Wuhan Healthgen Biotechnology Corp. (SHA:688765)
China
· Delayed Price · Currency is CNY 71.82
+1.49 (2.12%)
At close: Mar 6, 2026
SHA:688765 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 22.23 | 24.06 | 23.47 | 12.82 | 24.84 | 19.68 | Upgrade
|
| Other Revenue | 1.15 | 1.15 | 0.79 | 0.58 | 0.68 | 1.89 | Upgrade
|
| Revenue | 23.39 | 25.22 | 24.26 | 13.4 | 25.52 | 21.57 | Upgrade
|
| Revenue Growth (YoY) | -3.62% | 3.92% | 81.08% | -47.49% | 18.33% | 110.40% | Upgrade
|
| Cost of Revenue | 12.06 | 9.68 | 12.2 | 6.18 | 9.9 | 6.26 | Upgrade
|
| Gross Profit | 11.33 | 15.53 | 12.06 | 7.22 | 15.62 | 15.3 | Upgrade
|
| Selling, General & Admin | 82.21 | 63.35 | 58.84 | 58.99 | 71.31 | 32.84 | Upgrade
|
| Research & Development | 100.6 | 116.79 | 159.1 | 110.5 | 75.21 | 45.05 | Upgrade
|
| Other Operating Expenses | 6.63 | 1.85 | 1.77 | 0.77 | 0.28 | 0.15 | Upgrade
|
| Operating Expenses | 189.08 | 181.98 | 219.72 | 170.26 | 146.8 | 78.05 | Upgrade
|
| Operating Income | -177.75 | -166.45 | -207.66 | -163.04 | -131.18 | -62.74 | Upgrade
|
| Interest Expense | -7.24 | -5.1 | -0.66 | -0.23 | -0.53 | -0.97 | Upgrade
|
| Interest & Investment Income | 2.2 | 2.4 | 5.79 | 14.64 | 2.73 | 0.3 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.14 | -0.14 | -0.13 | 0.39 | -0.06 | -0.5 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.03 | -0.05 | -0.02 | 0 | -0.09 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | -182.91 | -169.34 | -202.68 | -148.24 | -129.13 | -63.95 | Upgrade
|
| Gain (Loss) on Sale of Assets | 3.35 | -1.28 | 1.01 | 0.33 | -11.27 | 2.08 | Upgrade
|
| Asset Writedown | -0.5 | - | -0 | - | 0 | - | Upgrade
|
| Legal Settlements | - | - | - | -1.49 | - | - | Upgrade
|
| Other Unusual Items | 19.25 | 19.25 | 14.71 | 5.82 | 6.36 | 8.52 | Upgrade
|
| Pretax Income | -160.81 | -151.37 | -186.96 | -143.58 | -134.04 | -53.35 | Upgrade
|
| Net Income | -160.81 | -151.37 | -186.96 | -143.58 | -134.04 | -53.35 | Upgrade
|
| Net Income to Common | -160.81 | -151.37 | -186.96 | -143.58 | -134.04 | -53.35 | Upgrade
|
| Shares Outstanding (Basic) | 270 | 270 | 267 | 261 | 216 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 270 | 270 | 267 | 261 | 216 | 50 | Upgrade
|
| Shares Change (YoY) | 1.21% | 1.20% | 2.31% | 20.75% | 333.57% | 4.84% | Upgrade
|
| EPS (Basic) | -0.59 | -0.56 | -0.70 | -0.55 | -0.62 | -1.07 | Upgrade
|
| EPS (Diluted) | -0.59 | -0.56 | -0.70 | -0.55 | -0.62 | -1.07 | Upgrade
|
| Free Cash Flow | -469.63 | -220.38 | -224.45 | -424.7 | -263.44 | -36.85 | Upgrade
|
| Free Cash Flow Per Share | -1.74 | -0.81 | -0.84 | -1.63 | -1.22 | -0.74 | Upgrade
|
| Gross Margin | 48.43% | 61.59% | 49.71% | 53.89% | 61.21% | 70.95% | Upgrade
|
| Operating Margin | -760.04% | -660.11% | -855.82% | -1216.74% | -514.08% | -290.94% | Upgrade
|
| Profit Margin | -687.60% | -600.28% | -770.53% | -1071.49% | -525.26% | -247.39% | Upgrade
|
| Free Cash Flow Margin | -2008.10% | -873.96% | -925.01% | -3169.45% | -1032.38% | -170.86% | Upgrade
|
| EBITDA | -115.58 | -106.92 | -160.56 | -150.66 | -121.52 | -52.63 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -244.06% | Upgrade
|
| D&A For EBITDA | 62.18 | 59.54 | 47.1 | 12.38 | 9.67 | 10.11 | Upgrade
|
| EBIT | -177.75 | -166.45 | -207.66 | -163.04 | -131.18 | -62.74 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -290.94% | Upgrade
|
| Advertising Expenses | - | 0.3 | 0.12 | 0.07 | 0.13 | 0 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.